Knoll Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Knoll Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,532	Closed	-$586K	–	37
2022 Q3	$586K	Sell	19,532 -3,609	-16%	-$887K	0.34%	18
2022 Q2	$4.37M	Hold	23,141	–	–	2.5%	3
2022 Q1	$5.76M	Hold	23,141	–	–	3.62%	3
2021 Q4	$3.6M	Hold	23,141	–	–	1.98%	6
2021 Q3	$4.64M	Hold	23,141	–	–	2.31%	7
2021 Q2	$5.92M	Hold	23,141	–	–	3.09%	7
2021 Q1	$6.14M	Hold	23,141	–	–	4%	7
2020 Q4	$8.53M	Buy	23,141 +3,300	+17%	+$947K	5.82%	3
2020 Q3	$4.84M	Buy	19,841 +2,333	+13%	+$726K	3.97%	5
2020 Q2	$5.06M	Buy	17,508 +1,667	+11%	+$491K	2.92%	6
2020 Q1	$3.23M	Buy	15,841 +4,166	+36%	+$1.33M	3.04%	7
2019 Q4	$5.22M	Hold	11,675	–	–	3.85%	6
2019 Q3	$3.59M	Hold	11,675	–	–	3.29%	8
2019 Q2	$3.71M	Buy	11,675 +9,167	+366%	+$3.17M	3.04%	8
2019 Q1	$1.05M	Hold	2,508	–	–	0.8%	14
2018 Q4	$764K	Hold	2,508	–	–	0.87%	10
2018 Q3	$910K	Hold	2,508	–	–	0.77%	13
2018 Q2	$918K	Hold	2,508	–	–	0.78%	12
2018 Q1	$741K	Buy	+2,508	New	+$741K	0.76%	11

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Knoll Capital Management's EIGR Position: Q4 2022 in Review

Knoll Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 19,532 shares — an estimated $586K sold.

Knoll Capital Management first reported a position in EIGR in Q1 2018 and held it in 19 quarters. The position peaked at $8.53M in Q4 2020. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

Knoll Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Knoll Capital Management sold 19,532 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $586K.
Knoll Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2018 and held it in 19 quarters.
Knoll Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $8.53M in Q4 2020.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Knoll Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.